News | Prostate Cancer | March 22, 2017

Profound Medical Corp. and Philips Announce First TULSA-PRO Sale in Finland

System combines real-time MRI with transurethral, robotically-driven ultrasound for prostate ablation

March 22, 2017 — Profound Medical Corp. announced that it has successfully completed the first sale of a TULSA-PRO system in Finland to the Turku University Hospital (“Tyks”). The deal was completed in collaboration with Philips, who is working in partnership with Profound to commercialize the TULSA-PRO system in Europe.

Profound has also sold TULSA-PRO systems in Spain, the United Kingdom and Germany since receiving CE Mark designation in April 2016.

Operation of the TULSA-PRO system will be administered under Roberto Blanco Sequeiros, M.D., chairman of the Medical Imaging Center at Turku University Hospital and under a leading European urologist, Peter Boström, M.D. According to Blanco Sequeiros, the technology holds promise in multiple areas of prostate treatment and care, including focal therapy for localized prostate cancer, treatment of benign prostate hyperplasia, salvage radiation therapy and the debulking of tumours.

“While there have been significant medical advances in prostate care in recent years, there is no question that an unmet medical need and uncharted medical terrain remains,” commented Blanco Sequeiros. “Survival rates for prostate cancer are high, but current therapies often come with side effects that include erectile dysfunction, incontinence and bowel problems. Though further testing is required, the evidence is compelling, and suggests that the TULSA-PRO system could represent a major breakthrough in prostate treatment, offering patients a therapy that is safe, accurate and effective with minimal side effects. We are keen to assess its potential in both localized prostate cancer and other prostate conditions.”

TULSA-PRO combines real-time magnetic resonance imaging (MRI) with transurethral, robotically-driven therapeutic ultrasound and closed-loop thermal feedback control designed to provide precise ablation of the prostate while simultaneously protecting critical surrounding anatomy from potential side effects. TULSA-PRO has demonstrated accurate and precise ablation of malignant prostate tissue, while providing a favorable safety profile, with low rates of serious or long-term adverse events.

Profound is currently conducting a pilot commercial launch of TULSA-PRO in key European and other CE mark jurisdictions. The company is also sponsoring a multicenter, prospective U.S. Food and Drug Administration (FDA)-registered clinical trial, TACT, which is designed to further demonstrate the safety and effectiveness of this innovative technology.  If successful, TACT is expected to support Profound's application to the FDA for approval to market TULSA-PRO in the United States.

For more information: www.profoundmedical.com

Related Content

Bringing the comfort of a personal movie theater into the magnetic resonance imaging (MRI) scanning procedure. Combining vivid video and symphonic-quality audio, Resonance Technology offers the ultimate in-patient comfort. CinemaVision is an immersive entertainment system with an MR Headset and Visor that helps to alleviate anxiety and claustrophobia by transporting patients to a breathtaking virtual world
News | Magnetic Resonance Imaging (MRI) | December 04, 2020
December 4, 2020 — Bringing the comfort of a personal movie theater into the...
For men with early-stage prostate cancer, choices about initial treatment carry varying risks of "financial toxicity," reports a study in The Journal of Urology, Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer.

Getty Images

News | Prostate Cancer | December 02, 2020
December 2, 2020 — ...
Samsung to highlight its medical imaging portfolio with its latest radiology innovations in ultrasound, digital radiography and mobile computed tomography
News | Radiology Imaging | December 02, 2020
December 2, 2020 — Samsung Electronics Co., Ltd.
By eliminating the need to move neonates from the NICU to the radiology department, Aspect Imaging’s Embrace enables a safer way to perform the MRI procedure
News | Magnetic Resonance Imaging (MRI) | December 01, 2020
December 1, 2020 — Based on its recent analysis of the global neonatal intensive care unit magnetic resonance imaging
Resoundant Inc., announced hat it has entered into a strategic partnership with United Imaging Healthcare to begin offering advanced magnetic resonance elastography (MRE) on leading United Imaging MRI systems.
News | Magnetic Resonance Imaging (MRI) | November 30, 2020
November 30, 2020 — Resoundant Inc., announced that it has entered into a strategic partnership with...
Chest CT images in a 34-year-old man with fever for 4 days. Positive result of reverse-transcription polymerase chain reaction assay for severe acute respiratory syndrome coronavirus 2 using a swab sample was obtained on February 8, 2020. Dates of examination are shown on images. A, Chest CT scan with magnification of lesions in coronal and sagittal planes shows a nodule with reversed halo sign in left lower lobe (box) at the early stage of the pneumonia. B, Chest CT scans in different axial planes and coro

Chest CT images in a 34-year-old man with fever for 4 days. Positive result of reverse-transcription polymerase chain reaction assay for severe acute respiratory syndrome coronavirus 2 using a swab sample was obtained on February 8, 2020. Dates of examination are shown on images. A, Chest CT scan with magnification of lesions in coronal and sagittal planes shows a nodule with reversed halo sign in left lower lobe (box) at the early stage of the pneumonia. B, Chest CT scans in different axial planes and coronal reconstruction show bilateral multifocal ground-glass opacities. The nodular opacity resolved.

News | Coronavirus (COVID-19) | November 29, 2020
November 29, 2020 — The Radiological Society of North America (...